

## Agenda for the Metastatic Breast Cancer (MBC) Engagement Conference at Moffitt Cancer Center

Note: \*\* Indicates presentations we are applying for CME credit for.

CER = comparative effectiveness research (research comparing the benefits and harms of existing approved MBC therapies to improve outcomes or quality of life)

<b>Friday, June 22, 2018</b>	<b>Saturday, June 23, 2018</b>
8-9:30 AM Registration in atrium of Stable Research Building at Moffitt	8:30-9:30AM <i>Session 5: Insurance Coverage of Therapies in Clinical Studies</i> (includes 15 min of Q&A)
9:30-9:40AM Welcoming remarks and announcements	9:30-10:45AM <i>Session 6: Clinical Advances Including Blood Based Diagnostics for MBC**</i>
9:40-9:45AM Introduction to the Patient-Centered Outcomes Research Institute (PCORI)	10:45-11AM <i>Break</i>
9:45-10:05AM <i>Session 1: Introduction to CER Trials**</i>	11AM-12:00 PM <i>Session 7: CER Trial Priorities for MBC**</i>
10:05-10:20 AM Break (registration still open)	12:00-12:40 PM Lunch at roundtables
10:20 AM-11AM <i>Session 2: MBC Patient-led Panel Presents Top Patient-Desired Outcomes**</i>	12:40-2:40 PM National CER Priorities Engagement Session in Working Groups (15 min. break inside the 2-hour session)
11AM-12:10PM <i>Session 3: Needs Assessment Panel Discussion for Identifying Barriers to Engagement (patients, clinicians, and researchers)</i>	2:45-3:20 PM <i>Session 8: MBC Stakeholder Resources</i> (includes resource information for patients, physicians and researchers)
12:10-1:30 PM Lunch at roundtables with 1 hour engagement session from 12:30-1:30 for discussion of important barriers to engagement amongst stakeholders	3:20-4:15 PM Networking reception to facilitate creation of new peer-to-peer support groups (hors d'oeuvres provided)
1:30 PM-2:45 PM <i>Session 4: Introduction to the Biology of Breast Cancer Metastasis and Current Translational Research**</i>	4:15-4:20 PM Closing Remarks

2:45 – 3PM Break	
3PM-4PM Engagement in working groups to order top translational/clinical research priorities 4-4:05 PM Brief announcement about directory participation for research studies/trials and sustained engagement	
4:05-5PM Networking Reception (hors d'oeuvres provided)	
5PM Dinner at roundtables	

#### Description of Sessions

**Session 1:** *Introduction to Clinical Comparative Effectiveness Research (CER) Trials for MBC*

Conference attendees (patients, clinicians and translational researchers) will be introduced to what CER is (a path forward for existing therapies to improve medical decisions) and how CER compares to phase III trials (describing the similarities and differences of CER and phase III trials for testing experimental therapies). Attendees will also be introduced to the PICOT format for writing clinical CER questions that address patient-desired research outcomes. 17-minute presentation with 3 minutes for questions.

**Session 2:** *MBC Patient-led Panel Presents Top Patient-Desired Outcomes*

A panel consisting of 5 MBC patient advocates will present their top stage IV patient-desired outcomes including clinical and patient-reported outcomes. Each patient should expect to present for up to 6 minutes with slides. There will be 10 minutes following the panel for input from the audience. The project lead will collate a list of all top patient-desired outcomes discussed for publication.

**Session 3:** *Needs Assessment Panel Discussion and Engagement Session for Identifying Barriers to Engagement Among Stakeholders (patients, researchers, clinicians)*

This session will serve to identify and discuss current barriers that must be overcome for successful engagement amongst clinicians, researchers, and patients to ensure metastasis research in the lab and in clinical trials remains patient-centered. The panel will consist of 1 researcher, 1 clinician scientist, 1 oncologist, and 2 patients (one male

and one female) to facilitate discussion of improving metastatic breast cancer studies through engagement from multiple perspectives.

Each panelist will present their barriers to engagement in an up to 6-minute presentation with slides. This will be followed by 30 minutes of discussion amongst panelists before input is opened to the audience for 20 minutes to conclude top barriers to engagement. The discussion will build upon barriers introduced during the first three webinars prior to the conference (these will be provided to speakers by the project lead by January of 2018, examples below).

Example barriers identified so far: Finding a way for patients who want to support and participate in research/trial planning to be matched with researchers/clinicians looking for their input, lack of researcher/clinician time, finding a balance between research needs and patient needs, etc.

**Session 4: *Introduction to the Biology of Breast Cancer Metastasis and Current Translational Research***

A translational metastatic breast cancer researcher of the Metastasis Research Society will introduce the top 5 translational metastatic breast cancer research priorities identified by a survey and explain the basic biology of metastasis related to each in lay terms. The goal is to introduce priority research topics and educate the audience as to why they are important biologically while at the same time teaching some of the basic biology of breast cancer metastasis. The presentation will be followed by engagement amongst conference attendees (patients, researchers, and clinicians) collectively in working groups to rank the top 3 translational metastatic breast cancer research priorities from the list of 5. There is 1 hour allotted for the presentation (up to 12 minutes per topic) with Q&A time to follow before the hour-long engagement session.

**Session 5: *Insurance Coverage of Therapies in Clinical Studies***

A panel of representatives from healthcare insurance companies will describe their coverage of therapies in cancer clinical trials (what they do and do not cover).

**Session 6: *Clinical Advances Including Blood Based Diagnostics for MBC\*\****

Two leading oncologists will collectively cover the most recent clinical comparative effectiveness research findings (comparisons of existing therapies) for male or female metastatic breast cancer in lay terminology in order to disseminate information on the benefits and harms of current therapy options to all stakeholders. Oncologists will also briefly touch on clinical trials with new experimental treatments for metastatic breast cancer. An additional oncologist will present on how available blood tests (liquid biopsy) can be used to manage and treat MBC. Each oncologist will have 15-22 minutes to present and this session will be followed by 15 minutes of Q&A.

*Example CER topics (final session topics to be announced):* comparison of third line treatment options for metastatic breast cancer, hormonal therapies versus non-hormonal therapies for hormone positive metastatic breast cancer, partial versus

whole-breast radiation, comparison of imaging modalities for diagnosing axillary lymph node metastasis, comparison of alternative mTOR inhibitors and alternative aromatase inhibitors.

**Session 7: CER Trial Priorities for MBC\*\***

An oncologist will introduce the top 6 comparative effectiveness research (CER) topics in no special order, identified by all stakeholders as important on a pre-conference survey. The speaker will identify the question the CER topic is meant to address i.e. explain the significance of each topic prior to discussions meant to prioritize these topics amongst all stakeholders in engagement working groups. If topics mention certain drugs the speaker should explain what the drug is intended to treat and how. The list of the top 6 priorities will be provided to the speaker by February of 2018 to allow 5 months to prepare for the 45-minute talk (7.5 minutes per priority).

Stakeholder working groups of patients, clinicians, and researchers will then discuss the 6 topics and come up with specific CER questions meant to address at least 1 of the topics they feel as a group is the most important and addresses patient-desired outcomes. All stakeholders will be given a template for developing questions related to CER topics and sample questions. There will be at least 20 min. of discussion time for each of the 6 topics.

**Session 8: Stakeholder Resources**

A representative of METAvivor will present on their established peer-to-peer support program for metastatic patients and clearly explain how individuals can set up these groups. Short presentations from two other patients will follow that highlight additional MBC patient resources to physicians, researchers and patients (stakeholders).